Your browser is no longer supported. Please, upgrade your browser.
Settings
EVFM [NASD]
Evofem Biosciences, Inc.
Index- P/E- EPS (ttm)-2.34 Insider Own2.20% Shs Outstand81.84M Perf Week-12.00%
Market Cap95.04M Forward P/E- EPS next Y-0.96 Insider Trans9.26% Shs Float81.07M Perf Month27.91%
Income-169.30M PEG- EPS next Q-0.41 Inst Own41.60% Short Float13.35% Perf Quarter-58.96%
Sales1.60M P/S59.40 EPS this Y-6.50% Inst Trans35.25% Short Ratio0.92 Perf Half Y-46.86%
Book/sh-0.17 P/B- EPS next Y40.70% ROA-150.20% Target Price- Perf Year-62.46%
Cash/sh- P/C- EPS next 5Y- ROE-702.10% 52W Range0.75 - 5.53 Perf YTD-54.36%
Dividend- P/FCF- EPS past 5Y35.40% ROI-131.30% 52W High-80.11% Beta-0.33
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin37.20% 52W Low46.47% ATR0.12
Employees147 Current Ratio1.10 Sales Q/Q- Oper. Margin- RSI (14)49.04 Volatility12.44% 8.31%
OptionableYes Debt/Eq- EPS Q/Q-41.90% Profit Margin- Rel Volume1.33 Prev Close1.16
ShortableYes LT Debt/Eq- EarningsMay 06 AMC Payout- Avg Volume11.72M Price1.10
Recom2.00 SMA2012.96% SMA50-10.81% SMA200-52.44% Volume15,554,400 Change-5.17%
Oct-02-20Initiated Stifel Buy $5
Aug-20-20Initiated Morgan Stanley Equal-Weight $3
Jun-08-20Initiated Piper Sandler Overweight $11
Oct-16-19Resumed Cantor Fitzgerald Overweight $9
Jun-01-21 09:00AM  
May-25-21 08:00AM  
May-21-21 06:50AM  
May-18-21 09:06AM  
May-17-21 11:02PM  
04:02PM  
08:00AM  
May-12-21 04:19PM  
09:00AM  
May-06-21 04:01PM  
02:30PM  
Apr-28-21 11:00AM  
Apr-22-21 08:00AM  
Apr-21-21 08:00AM  
Mar-29-21 04:05PM  
Mar-25-21 07:58AM  
Mar-24-21 10:00PM  
04:00PM  
Mar-17-21 08:00AM  
Mar-16-21 08:00AM  
Mar-06-21 03:05AM  
Mar-05-21 01:00PM  
10:38AM  
Mar-04-21 04:00PM  
02:30PM  
Feb-23-21 08:00AM  
Feb-18-21 08:00AM  
Feb-16-21 08:00AM  
Feb-04-21 09:00AM  
Jan-12-21 09:05AM  
Dec-22-20 07:00AM  
Dec-21-20 09:00AM  
Dec-17-20 07:00AM  
Dec-12-20 03:12PM  
Dec-11-20 08:00AM  
Dec-03-20 07:00AM  
Nov-20-20 08:30AM  
Nov-12-20 08:30AM  
Nov-09-20 11:00PM  
04:01PM  
03:15PM  
Oct-27-20 08:00AM  
Oct-26-20 09:00AM  
Oct-20-20 08:00AM  
Oct-08-20 10:15AM  
Oct-07-20 08:00AM  
Sep-16-20 12:13PM  
Sep-14-20 09:42AM  
09:00AM  
Sep-11-20 12:02PM  
10:27AM  
Sep-07-20 11:57AM  
Aug-31-20 09:00AM  
Aug-21-20 06:00PM  
Aug-20-20 09:51AM  
Aug-11-20 08:53AM  
Aug-04-20 09:31PM  
08:00AM  
Aug-03-20 08:30AM  
Jul-23-20 08:30AM  
Jul-21-20 03:55AM  
03:55AM  
Jul-15-20 08:30AM  
Jul-01-20 08:01AM  
Jun-29-20 09:33AM  
Jun-26-20 08:44AM  
Jun-12-20 08:08AM  
Jun-03-20 12:31PM  
Jun-02-20 11:03PM  
04:01PM  
May-31-20 05:15PM  
May-28-20 06:30AM  
May-27-20 10:56AM  
08:55AM  
May-26-20 10:32AM  
09:52AM  
09:00AM  
08:42AM  
May-22-20 04:37PM  
04:05PM  
01:09PM  
01:07PM  
01:07PM  
May-21-20 04:05PM  
May-18-20 04:05PM  
May-13-20 08:00AM  
May-08-20 09:00AM  
May-07-20 07:30AM  
May-06-20 08:00AM  
May-01-20 05:21PM  
Apr-28-20 08:00AM  
Apr-24-20 08:30AM  
Apr-19-20 07:02AM  
Apr-10-20 04:05PM  
Mar-30-20 05:14PM  
Mar-27-20 08:30AM  
Mar-25-20 05:00PM  
Mar-24-20 04:00PM  
Mar-19-20 08:15AM  
Mar-12-20 09:00AM  
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Brien Anthony StephenDirectorJun 14Buy1.318,14010,6638,140Jun 14 04:13 PM
Rarick Lisa DaleDirectorJun 11Buy1.205,0005,99010,250Jun 14 04:14 PM
Barrans RussellChief Commercial OfficerJun 11Buy1.1418,18020,725468,552Jun 11 08:19 PM
File Justin J.Chief Financial OfficerJun 10Buy1.0324,50025,235440,388Jun 10 07:30 PM
Fitzpatrick Alexander AGeneral Counsel and SecretaryJun 10Buy1.0210,00010,250311,422Jun 10 07:29 PM
PELLETIER SAUNDRA LChief Executive OfficerJun 10Buy1.0350,00051,500850,837Jun 10 07:30 PM
PELLETIER SAUNDRA LChief Executive OfficerMar 09Buy2.2845,249103,168906,137Mar 09 06:59 PM
File Justin J.Chief Financial OfficerNov 17Buy2.177,76016,839258,168Nov 18 05:22 PM
Fitzpatrick Alexander AGeneral Counsel and SecretaryNov 17Buy2.209,09019,998143,542Nov 18 05:14 PM
Barrans RussellChief Commercial OfficerSep 11Buy2.083,0006,240279,052Sep 11 05:20 PM
Barrans RussellChief Commercial OfficerSep 10Buy2.711,0002,710276,052Sep 11 05:20 PM
PELLETIER SAUNDRA LChief Executive OfficerSep 08Sale3.26122,500399,350360,888Sep 10 08:04 PM